NTRK1 and breast carcinoma: Currently, in breast cancer, especially in TNBC, multiple clinical trials of the application of combined immune checkpoint inhibitors with antiangiogenic drugs, such as multitarget receptor tyrosine kinase inhibitor anlotinib and small-molecule tyrosine kinase inhibitor apatinib (VEGFR2 inhibitor), which are manufactured in China, are being carried out (NCT03855358, NCT04914390, NCT04877821, NCT04405505, NCT04722718, NCT04303741, NCT03945604, and NCT03394287, et al.).